^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CDK6 expression

    i
    Other names: CDK6, PLSTIRE, Cyclin-dependent kinase 6
    Entrez ID:
    1021
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Associations

    News

    Trials
    15d
    Maslinic acid induces autophagy and ferroptosis via transcriptomic and metabolomic reprogramming in prostate cancer cells. (PubMed, Front Pharmacol)
    In vivo, we demonstrated that 50 mg/kg MA significantly inhibited the growth of tumors established using RM-1 cells. To summarize, we report that MA inhibits prostate cancer cell growth both in vitro and in vivo by inducing autophagy and ferroptosis via transcriptomic and metabolomic reprogramming.
    Journal • Metabolomic study
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • mTOR (Mechanistic target of rapamycin kinase) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • GPX4 (Glutathione Peroxidase 4) • CDK2 (Cyclin-dependent kinase 2) • SLC7A11 (Solute Carrier Family 7 Member 11) • ATG5 (Autophagy Related 5) • NFKBIA (NFKB Inhibitor Alpha 2) • ABCA1 (ATP Binding Cassette Subfamily A Member 1) • ATG7 (Autophagy Related 7) • BECN1 (Beclin 1) • JUN (Jun proto-oncogene)
    |
    TP53 expression • GPX4 expression • CDK6 expression
    22d
    A molecular and immunohistochemical study of 37 cases of ovarian Sertoli-Leydig cell tumor. (PubMed, Virchows Arch)
    DICER1MUT and DICER1WT tumors showed different mRNA expression profiles. The FOXL2 mutation is less common in these tumors and is mutually exclusive with the DICER1 mutation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • TERT (Telomerase Reverse Transcriptase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • NOTCH2 (Notch 2) • CDK6 (Cyclin-dependent kinase 6) • CA9 (Carbonic anhydrase 9) • MUC4 (Mucin 4, Cell Surface Associated) • DICER1 (Dicer 1 Ribonuclease III) • CD99 (CD99 Molecule) • PRKCA (Protein Kinase C Alpha) • FOXL2 (Forkhead Box L2) • HNF1A (HNF1 Homeobox A)
    |
    PD-L1 negative • PTEN expression • TERT mutation • TERT promoter mutation • CTLA4 expression • MUC4 expression • CA9 expression • CDK6 expression
    26d
    Nicotinamide mononucleotide protects STAT1 from oxidative stress-induced degradation to prevent colorectal tumorigenesis. (PubMed, MedComm (2020))
    These results indicate that oxidative stress induces STAT1 degradation in tumor cells and possibly in CAC tissues, whereas supplementation with NMN protects STAT1 from oxidation-induced degradation and prevents tumorigenesis. This study provides experimental evidence for the development of NMN-mediated chemoprevention strategies for CRC.
    Journal
    |
    CDK6 (Cyclin-dependent kinase 6) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    CDK6 expression
    1m
    Lnc NEAT1 facilitates the progression of melanoma by targeting the miR-152-3p/CDK6 axis: An observational study. (PubMed, Medicine (Baltimore))
    Furthermore, the miR-152-3p/ CDK6 axis was implicated in the progression of melanoma accelerated by Lnc NEAT1. Taken together, Lnc NEAT1 may promote melanoma development by serving as an endogenous sponge of miR-152-3p, increasing CDK6 expression, and identifying a new target for the treatment of melanoma.
    Observational data • Journal
    |
    CDK6 (Cyclin-dependent kinase 6) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • MIR152 (MicroRNA 152)
    |
    CDK6 expression
    2ms
    Anti colorectal cancer activity and in silico studies of novel pyridine nortopsentin analog as cyclin dependent kinase 6 inhibitor. (PubMed, Sci Rep)
    4i also demonstrated a high potential for oral bioavailability due to its adherence to Lipinski's rule of five. The molecular docking studies of 4i analog showed good binding mode with CDK6 active pocket through the formation of multiple interactions with its key amino acids.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CDK2 (Cyclin-dependent kinase 2)
    |
    CDK2 expression • CDK6 expression
    2ms
    Key Genes Involved in the Beneficial Mechanism of Hyperbaric Oxygen for Glioblastoma and Predictive Indicators of Hyperbaric Oxygen Prolonging Survival in Glioblastoma Patients. (PubMed, Curr Med Sci)
    HBO is beneficial for glioblastoma. Glioblastoma patients with these predictive indicators may prolong survival with HBO therapy. These potential therapeutic targets especially COL1A1, ADAMTS1 and PTBP3 deserve further validation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NF1 (Neurofibromin 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PD-1 (Programmed cell death 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • MDM4 (The mouse double minute 4) • CDK6 (Cyclin-dependent kinase 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CA9 (Carbonic anhydrase 9) • COL1A1 (Collagen Type I Alpha 1 Chain) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • ADAMTS1 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 1) • CDC42 (Cell Division Cycle 42) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • DDIT3 (DNA-damage-inducible transcript 3) • IGFBP3 (Insulin-like growth factor binding protein 3) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5) • BAK1 (BCL2 Antagonist/Killer 1) • CDC25A (Cell Division Cycle 25A) • COL12A1 (Collagen Type XII Alpha 1 Chain) • COL8A1 (Collagen Type VIII Alpha 1 Chain) • EFEMP1 (EGF Containing Fibulin Extracellular Matrix Protein 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MCM2 (Minichromosome maintenance complex component 2) • RHOJ (Ras Homolog Family Member J) • NLRP2 (NLR Family Pyrin Domain Containing 2)
    |
    TP53 expression • CXCL12 expression • CDK6 expression • CDKN1B expression • PCNA expression
    2ms
    Enhancing radiosensitivity in osteosarcoma via CDKN2C overexpression: A mechanism involving G1 phase arrest mediated by inhibition of CDK4 expression and Thr172 phosphorylation. (PubMed, Biochem Biophys Res Commun)
    Our research results indicate that overexpression of CDKN2C enhances radiosensitivity in osteosarcoma through the induction of G1 phase arrest and subsequent apoptosis. G1 phase arrest is mediated by the suppression of CDK4 expression and Thr172 phosphorylation, which consequently affects the expression of phosphorylated RB at the Ser807/811 sites.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C)
    |
    CCND1 expression • BAX expression • CCND1 expression + CDK4 expression • CDK6 expression
    3ms
    Study on the Role of EPHB6 in Inhibiting the Malignant Progression of Cervical Cancer C33A Cells by Binding to CBX7. (PubMed, Cell Biochem Biophys)
    EPHB6 expression is reduced in cervical cancer tissues and cells. Its overexpression inhibits proliferation, invasion, migration, and cell cycle acceleration in C33A cells, exhibiting synergy when bound to CBX7.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
    |
    CDK6 expression
    3ms
    Umbelliprenin improved anti-proliferative effects of ionizing radiation on adult T-cell leukemia/lymphoma cells via interaction with CDK6; an in vitro and in silico study. (PubMed, Int J Immunopathol Pharmacol)
    Molecular docking revealed a favorable binding interaction between UMB and the ATP-binding site of CDK6, with a JAMDA score of -2.131, surpassing the control selonsertib. The current study provides evidence that UMB enhances the anti-proliferative effects of IR on ATL cells, and highlights the significance of targeting CDK6 in combinatorial approaches.
    Preclinical • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD44 (CD44 Molecule) • CDK6 (Cyclin-dependent kinase 6) • CFLAR (CASP8 and FADD-like apoptosis regulator) • ANXA5 (Annexin A5)
    |
    MYC overexpression • CDK6 overexpression • CDK6 expression
    3ms
    CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis. (PubMed, Int J Med Sci)
    These results indicated that CDK6 is an independent biomarker for predicting prognosis and immunotherapy efficacy of bladder cancer. A deeper understanding of its specific molecular mechanisms may provide new treatment strategies.
    Retrospective data • Journal • IO biomarker
    |
    CDK6 (Cyclin-dependent kinase 6)
    |
    CDK6 expression
    3ms
    Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway. (PubMed, Bioorg Chem)
    Furthermore, our results demonstrated that LB showed potential anti-Ex20ins cancer activity through suppression of the EGFR and ERK1/2 signaling pathway in Ba/F3 cells bearing two to three amino acid insertion mutations. These findings suggested that LB might be valuable for further investigation as a potential candidate in the treatment of associated diseases.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CCNA2 (Cyclin A2)
    |
    EGFR mutation • EGFR exon 20 insertion • CCND1 expression • TP53 expression • CDK6 expression • CDKN1B expression
    4ms
    KIFC3 promotes the proliferation, migration and invasion of non-small cell lung cancer through the PI3K/AKT signaling pathway. (PubMed, Sci Rep)
    This promotion effect could be inhibited by a specific inhibitor of the PI3K/Akt pathway, LY294002. Co-immunoprecipitation assays confirmed the interaction between endogenous/exogenous KIFC3 and PI3Kp85α. Tumor formation experiments in nude mice confirmed that KIFC3 overexpression promoted the proliferation, migration and invasion of NSCLC cells in vivo and performed its biological function through the PI3K/Akt signaling pathway.In conclusion, KIFC3 promotes the malignant behavior of NSCLC cells through the PI3K/Akt signaling pathway.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • MMP2 (Matrix metallopeptidase 2) • RHOA (Ras homolog family member A)
    |
    CCND1 expression • CDK6 expression
    |
    LY294002
    7ms
    Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia. (PubMed, Int J Mol Sci)
    Based on experimental transcriptomic data, we performed hierarchical modeling and determined cyclin-dependent kinase 6 (CDK6), tumor necrosis factor alpha (TNF-alpha), and transcriptional repressor CUX1 as the key regulators of the molecular response to the ATRA treatment in HL-60, NB4, and K562 cell lines, respectively. Mapping the data of TMT-based mass-spectrometric profiling on the modeling schemes, we determined CDK6 expression at the proteome level and its down-regulation at the transcriptome and proteome levels in cells treated with ATRA for 72 h. The combination of therapy with a CDK6 inhibitor (palbociclib) and ATRA (tretinoin) could be an alternative approach for the treatment of acute myeloid leukemia (AML).
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CDK6 (Cyclin-dependent kinase 6) • CUX1 (cut like homeobox 1)
    |
    CDK6 expression
    |
    Ibrance (palbociclib)
    7ms
    Tris(1,3-dichloro-2-propyl) phosphate-induced cytotoxicity and its associated mechanisms in human A549 cells. (PubMed, Toxicol Ind Health)
    In addition, cell apoptosis was induced via altering the expression levels of Bcl-2, BAX, and BAK. Our study implies that TDCIPP may pose potential health risks to the human respiratory system and its toxicity should not be neglected.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • BAX (BCL2-associated X protein) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    BCL2 expression • CCND1 expression • BAX expression • CDK6 expression • CDKN1B expression
    8ms
    Role and mechanism of NCAPD3 in promoting malignant behaviors in gastric cancer. (PubMed, Front Pharmacol)
    Moreover, NCAPD3 loss activates IRF7 and DDIT3 to regulate apoptosis in gastric cancer cells. Our study revealed that NCAPD3 silencing attenuates malignant phenotypes of GC and that it is a potential target for GC treatment.
    Journal
    |
    ER (Estrogen receptor) • CCND1 (Cyclin D1) • CDK6 (Cyclin-dependent kinase 6) • DDIT3 (DNA-damage-inducible transcript 3) • IRF7 (Interferon Regulatory Factor 7)
    |
    ER expression • CDK6 expression
    8ms
    FAM83B promotes cell proliferation via regulating the expression of CDK4/CDK6/CCND1 complex in laryngeal squamous cell carcinoma. (PubMed, Heliyon)
    Collectively, this study demonstrates that FAM83B serves as an oncogene in LSCC, promoting cell proliferation by controlling the protein expression of CDK4, CDK6, and CCND1, thus inducing a transference of the G1 stage to S stage in cell-cycle of LSCC cells. These results provide an academic foundation for elucidating the mechanism of LSCC occurrence and evolution and for developing treatment strategies for LSCC.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
    |
    CCND1 expression • CCND1 expression + CDK4 expression • CDK6 expression
    8ms
    Apoptotic Effect of Isoimpertorin via Inhibition of c-Myc and SIRT1 Signaling Axis. (PubMed, Int J Mol Sci)
    Furthermore, Isoimperatorin suppressed the overexpression of c-Myc by the proteasome inhibitor MG132 and also disturbed cycloheximide-treated c-Myc stability in Huh7 cells. Overall, these findings support the novel evidence that the pivotal role of c-Myc and SIRT1 is critically involved in Isoimperatorin-induced apoptosis in HCCs as potent molecular targets in liver cancer therapy.
    Journal • PARP Biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SIRT1 (Sirtuin 1)
    |
    MYC overexpression • MYC expression • CCND1 expression • CCNE1 expression • CDK2 expression • CDK6 expression
    |
    MG132
    8ms
    Curcumin inhibits the growth and invasion of gastric cancer by regulating long noncoding RNA AC022424.2. (PubMed, World J Gastrointest Oncol)
    Curcumin has potential anticancer effects on gastric cancer cells by regulating lncRNA AC022424.2. This lncRNA plays a significant role in cancer cell behavior and may have clinical implications in diagnosis and prognosis evaluation. The results of this study enhance our understanding of gastric cancer development and precision treatment.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    |
    BCL2 expression • BAX expression • CDK6 expression
    8ms
    hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma: in-silico and in-vitro study. (PubMed, EXCLI J)
    Compared to temozolomide, the combined treatment significantly decreased CDK4, CDK6, CCND1, and MMP2 expression. hsa-miR-34a-5p targets RAF1, as the signaling factor of the MAPK pathway, and potentiates the temozolomide anti-tumoral effect on A172 cells.
    Preclinical • Journal
    |
    PD-L1 (Programmed death ligand 1) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • MIR34A (MicroRNA 34a-5p) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • ANXA5 (Annexin A5)
    |
    MET expression • CCND1 expression • CDK6 expression
    |
    temozolomide
    8ms
    LncRNA RPL22P1-201 affects prostate cancer cell proliferation, cell cycle, and sensitivity to docetaxel by regulating miR-216b-5p expression (PubMed, Zhonghua Nan Ke Xue)
    RPL22P1-201 is highly expressed in prostate cancer, and silencing RPL22P1-201 inhibits prostate cancer PC3 cell proliferation and cell cycle by increasing miR-216b-5p expression, and enhances PC3 cell sensitivity to docetaxel.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3)
    |
    CDK6 expression
    |
    docetaxel
    8ms
    Inhibition of Proliferation and Induction of Apoptosis in Prostatic Carcinoma DU145 Cells by Polysaccharides from Yunnan Rosa roxburghii Tratt. (PubMed, Molecules)
    Rosa roxburghii Tratt polysaccharides, consisting of D-mannose, L-rhamnose, N-acetyl-D-glucosamine, D-galacturonic acid, D-glucose, D-galactcose, D-xylose, L-arabinose, and L-fucose, possess the ability to hinder DU145 cell proliferation, migration, and invasion while inducing apoptosis through the modulation of relevant protein and gene expressions.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
    |
    CCND1 expression • BAX expression • CDK6 expression
    8ms
    A narrative review on therapeutic potential of naringenin in colorectal cancer: Focusing on molecular and biochemical processes. (PubMed, Cell Biochem Funct)
    Based on the findings of this study, NAR is a potential therapeutic agent for CRC. Additional pharmacology and pharmacokinetics studies are required to fully elucidate the mechanisms of action of NAR and establish the most suitable dose for subsequent clinical investigations.
    Review • Journal • IO biomarker
    |
    ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • BIRC3 (Baculoviral IAP repeat containing 3) • CDK6 (Cyclin-dependent kinase 6) • BAX (BCL2-associated X protein) • CDK7 (Cyclin Dependent Kinase 7)
    |
    TP53 expression • BAX expression • CDK6 expression
    8ms
    MicroRNA-34a-5p: A pivotal therapeutic target in gallbladder cancer. (PubMed, Mol Ther Oncol)
    In a murine xenograft model, locally injected microRNA-34a-5p mimics significantly inhibited gallbladder cancer progression and downregulated CDK6 expression. These results provide a rationale for promising therapeutics against gallbladder cancer by microRNA-34a-5p injection, as well as a strategy to explore therapeutic targets against cancers using organoid-based models, especially for those lacking useful genetically engineered murine models, such as gallbladder cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CDK6 (Cyclin-dependent kinase 6) • MIR34A (MicroRNA 34a-5p)
    |
    KRAS G12D • KRAS G12 • CDK6 expression
    9ms
    Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells. (PubMed, Biomol Concepts)
    An anti-correlation expression pattern was found among the miR-34a-5p and miR-146a-5p and the respective target hub genes in WA-treated TNBC cells. In conclusion, WA might exert anti-cancer effect in TNBC cells by inducing miR-34a-5p and miR-146a-5p expressions and decreasing CCND1, CDK6, and TARF6 target hub genes in TNBC cells.
    Journal • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRCA1 (Breast cancer 1, early onset) • NOTCH1 (Notch 1) • CCND1 (Cyclin D1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NOTCH2 (Notch 2) • JAK1 (Janus Kinase 1) • CDK6 (Cyclin-dependent kinase 6) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • MIR34A (MicroRNA 34a-5p) • TGFB1 (Transforming Growth Factor Beta 1) • JAG1 (Jagged Canonical Notch Ligand 1) • SIRT1 (Sirtuin 1) • CDK3 (Cyclin Dependent Kinase 3) • E2F3 (E2F transcription factor 3) • TRAF6 (TNF Receptor Associated Factor 6)
    |
    CCND1 expression • miR-146a expression • CDK6 expression
    9ms
    PCID2 is highly expressed in gastric cancer and affects the prognosis by regulating cancer cell cycle and proliferation (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    PCID2 is highly expressed in gastric cancer tissues in close correlation with poor prognosis of the patients. High PCID2 expression promotes gastric cancer proliferation and cell cycle progression by inhibiting the expression of p27 and p16.
    Journal
    |
    CCND1 (Cyclin D1) • CDK6 (Cyclin-dependent kinase 6) • CA 19-9 (Cancer antigen 19-9)
    |
    CCND1 expression • CDK6 expression • CDKN1B expression
    10ms
    CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma. (PubMed, Hemasphere)
    Furthermore, we observed that patients who underwent lenalidomide-comprising induction therapy had significantly shorter progression-free survival when their samples were CDK6 positive. These data support that CDK6 protein expression is a marker for aggressive and drug-resistant disease and describes a potential drug target in MM.
    Journal
    |
    CDK6 (Cyclin-dependent kinase 6)
    |
    CDK6 expression
    |
    lenalidomide
    10ms
    Fisetin enhances cisplatin sensitivity in renal cell carcinoma via the CDK6/PI3K/Akt/mTOR signaling pathway. (PubMed, Oncol Lett)
    Overexpression of CDK6 neutralized the positive effects of fisetin on the improvement of cisplatin sensitivity in RCC cells. In conclusion, fisetin may enhance the sensitivity of RCC cells to cisplatin via the CDK6/PI3K/Akt/mTOR signaling pathway.
    Journal
    |
    CDK6 (Cyclin-dependent kinase 6)
    |
    CDK6 overexpression • CDK6 expression
    |
    cisplatin
    10ms
    Long noncoding RNA LINC00675 drives malignancy in acute myeloid leukemia via the miR-6809 -CDK6 axis. (PubMed, Pathol Res Pract)
    A high level of LINC00675 expression may make patients more susceptible to palbociclib treatments. In conclusion, our study demonstrated that LINC00675 is an oncogenic lncRNA that enhances the malignancy of AML by upregulating CDK6 expression through miR-6809 sponging, providing a new perspective and feasible target for the diagnosis and treatment of AML.
    Journal
    |
    CDK6 (Cyclin-dependent kinase 6)
    |
    CDK6 expression
    |
    Ibrance (palbociclib)
    11ms
    Jaceosidin induces apoptosis and inhibits migration in AGS gastric cancer cells by regulating ROS-mediated signaling pathways. (PubMed, Redox Rep)
    Furthermore, N-acetyl cysteine pre-treatment prevented the change of these protein expressions. In summary, JAC induced apoptosis and G0/G1 phase arrest and inhibited migration through ROS-mediated signaling pathways in AGS cells.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CDK6 (Cyclin-dependent kinase 6) • CDK2 (Cyclin-dependent kinase 2) • CDH2 (Cadherin 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    CCND1 expression • CDH1 expression • CDK2 expression • CDK6 expression
    11ms
    MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma. (PubMed, Drug Resist Updat)
    MAFF suppresses tumor growth, and pharmacological agonists targeting MAFF may improve cisplatin or irradiation therapies for lung adenocarcinoma patients.
    Journal
    |
    CDK6 (Cyclin-dependent kinase 6) • SLC7A11 (Solute Carrier Family 7 Member 11) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C) • CREB1 (CAMP Responsive Element Binding Protein 1)
    |
    SLC7A11 expression • CDK6 expression
    |
    cisplatin
    11ms
    An Essential Role of c-Fos in Notch1-mediated Promotion of Proliferation of KSHV-Infected SH-SY5Y Cells. (PubMed, Curr Mol Pharmacol)
    Our findings strongly indicate that c-Fos plays a crucial role in the promotion of cell proliferation through Notch1 signaling in KSHV-infected cells. Furthermore, our results suggest that the inhibition of expression of key viral pathogenic proteins is likely involved in this process.
    Journal
    |
    NOTCH1 (Notch 1) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
    |
    CCND1 expression • CCND1 expression + CDK4 expression • CDK6 expression
    |
    LY-411575
    11ms
    Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer. (PubMed, Br J Cancer)
    CDK6 expression was correlated with prognosis and therapy response in MIBC. Integration of CDK6, PD-L1 and TMB could better identify patients who were most likely to benefit from ICB and chemotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CDK6 (Cyclin-dependent kinase 6)
    |
    CDK6 expression
    11ms
    KNSTRN Is a Prognostic Biomarker That Is Correlated with Immune Infiltration in Breast Cancer and Promotes Cell Cycle and Proliferation. (PubMed, Biochem Genet)
    In conclusion, our study demonstrates that KNSTRN functions as an oncogene in breast cancer by regulating immune response, promoting G1/S transition, and facilitating breast cancer cell proliferation. Moreover, KNSTRN has potential as a molecular biomarker for diagnostic and prognostic prediction in breast cancer.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CCND3 (Cyclin D3) • SPAG5 (Sperm Associated Antigen 5)
    |
    CDK6 expression
    12ms
    Boswellia carterii oleoresin extracts induce caspase-mediated apoptosis and G cell cycle arrest in human leukaemia subtypes. (PubMed, Front Pharmacol)
    Cytotoxic mechanisms likely include activation of the intrinsic apoptotic pathway and cell cycle arrest through downregulation of CDK2, CDK6, cyclin D1, and cyclin D3. Our findings suggest that B. carterii may be an important source of novel chemotherapeutic drugs and justifies further investigation.
    Journal
    |
    CCND1 (Cyclin D1) • CDK6 (Cyclin-dependent kinase 6) • CASP3 (Caspase 3) • CCND3 (Cyclin D3) • CDK2 (Cyclin-dependent kinase 2) • ANXA5 (Annexin A5)
    |
    CCND1 expression • CDK2 expression • CDK6 expression
    1year
    Prognostic model for assessing the human glioma cell malignancy grade based on MDM2, MELK, SOX2, CDK4, DR5 and OCT4 gene expression. (PubMed, Zh Vopr Neirokhir Im N N Burdenko)
    We obtained a prognostic model for assessing the grade III and IV glioma cell malignancy based on expression of marker genes MDM2, MELK, SOX2, CDK4, DR5 and OCT4. Predictive accuracy was 83% (Akaike information criterion -55.125).
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • NOTCH2 (Notch 2) • TUBB3 (Tubulin beta 3 class III) • CDK6 (Cyclin-dependent kinase 6) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • PDGFA (Platelet Derived Growth Factor Subunit A) • PDGFB (Platelet Derived Growth Factor Subunit B) • L1CAM (L1 cell adhesion molecule) • NANOG (Nanog Homeobox) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
    |
    CD133 expression • CDK6 expression
    1year
    Molecular and immune landscape by cyclin dependent kinase (CDK) 4/6 expression and TP53 mutational status in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). (ASCO-GI 2024)
    Our comprehensive analysis is the first to show distinct mutational profiles according to TP53 mut status, and differential expression of immune-related genes and TME cell infiltration independent of TP53 mut in CDK4/6 high vs low dMMR/MSI-H CRC. In our series, CDK6 expression correlated with ICI treatment benefit in TP53 mut tumors, warranting further studies to explore the potential of targeting the CDK4/6 axis to enhance ICI efficacy in CRC.
    Microsatellite instability • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker • Mismatch repair
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • MSI (Microsatellite instability) • DNMT3A (DNA methyltransferase 1) • ARID1A (AT-rich interaction domain 1A) • PD-1 (Programmed cell death 1) • KMT2A (Lysine Methyltransferase 2A) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CDH1 (Cadherin 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • FANCL (FA Complementation Group L) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • HNF1A (HNF1 Homeobox A)
    |
    TP53 mutation • KRAS mutation • MSI-H/dMMR • BRAF mutation • ARID1A mutation • DNMT3A mutation • APC mutation • NF2 mutation • TP53 expression • MLL mutation • CDK4 mutation • CDK6 expression
    |
    MI Tumor Seek™
    1year
    Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation. (PubMed, Eur J Med Chem)
    Moreover, 10 exhibited remarkable pharmacokinetic properties and significant antitumor efficacy in vivo. Therefore, compound 10 may represent a new, potent and selective BET bromodomain inhibitor for the development of therapeutics to treat AML.
    Journal • PARP Biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CDK6 (Cyclin-dependent kinase 6) • BRD4 (Bromodomain Containing 4) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    MYC expression • CDK6 expression
    1year
    AHSA1 Regulates Hepatocellular Carcinoma Progression via the TGF-β/Akt-Cyclin D1/CDK6 Pathway. (PubMed, J Hepatocell Carcinoma)
    AHSA1 might serve as a biomarker for predicting the clinical outcome of patients with HCC. It is vital in tumor metastasis and disease progression of HCC and may facilitate the development of clinical intervention strategies against HCC.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • CDK6 (Cyclin-dependent kinase 6) • CCND3 (Cyclin D3) • TGFB1 (Transforming Growth Factor Beta 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    CCND1 expression • CDK6 expression
    1year
    8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML Treatment. (PubMed, Biomolecules)
    Overall, this study provides insights into the therapeutic applications of 8-OHD in treating AML and elucidates its underlying mechanisms of action.
    Journal • PARP Biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • TERT (Telomerase Reverse Transcriptase) • CDK6 (Cyclin-dependent kinase 6) • CCND2 (Cyclin D2) • CASP7 (Caspase 7)
    |
    CDK6 expression
    |
    cytarabine
    1year
    LncRNA INHEG promotes glioma stem cell maintenance and tumorigenicity through regulating rRNA 2'-O-methylation. (PubMed, Nat Commun)
    INHEG activation enhances rRNA 2-O-methylation, thereby increasing the expression of oncogenic proteins including EGFR, IGF1R, CDK6 and PDGFRB in glioma cells. Taken together, this study identifies a lncRNA that connects snoRNP-guided rRNA 2'-O-methylation to upregulated protein translation in GSCs, supporting an axis for potential therapeutic targeting of gliomas.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CDK6 (Cyclin-dependent kinase 6) • TAF15 (TATA-Box Binding Protein Associated Factor 15)
    |
    CDK6 expression
    1year
    Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells. (PubMed, Int Immunopharmacol)
    Due to high heterogeneity of DLBCL, 30-40 % of patients are resistant to R-CHOP standard chemoimmunotherapy...Further research indicated the pre-treatment with ROS scavenger N-acetylcysteine (NAC) and JNK inhibitor SP600125 could partially attenuate apoptosis and DNA damage triggered by DCZ0358. Most importantly, DCZ0358 exhibited synergistic anti-tumor effects when combined with etoposide, a common clinical anti-DLBCL drug, both in vitro and certainly in vivo. Above results demonstrated anti-tumor molecular mechanism of DCZ0358 in DLBCL cells and highlighted the ROS/JNK/DNA damage pathway as a potential target in therapies, which have implications for the development of more effective clinical treatments for DLBCL.
    Journal • IO biomarker
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
    |
    CCND1 expression • CCND1 expression + CDK4 expression • CDK6 expression
    |
    Rituxan (rituximab) • etoposide IV • SP600125
    1year
    In silico analysis of prognostic and diagnostic significance of target genes from prostate cancer cell lines derived exomicroRNAs. (PubMed, Cancer Cell Int)
    ExomiRNAs-targets genes, TNRC6B, CDK6, and AGO1, showed a deregulated expression profile in PCa tissue and could be useful for PCa diagnosis and prognosis.
    Preclinical • Journal
    |
    CDK6 (Cyclin-dependent kinase 6)
    |
    CDK6 expression